New funding will scale CytoReason’s AI platform, expand disease models, and support a new office in Cambridge, MA.
July 17, 2024 – Tel Aviv, Israel
CytoReason, a leader in AI-powered disease modeling for pharma R&D, has secured $80 million in funding from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific. The investment will fuel the expansion of its disease model portfolio, grow its proprietary clinical datasets, and support the company’s U.S. expansion with a new office in Cambridge, Massachusetts.
The funding comes at a time when pharmaceutical companies are seeking smarter, faster ways to prioritize assets and improve clinical success rates. CytoReason’s technology delivers molecular-level insights that accelerate drug development decisions across therapeutic areas like immunology, oncology, and CNS disorders.
Since its expanded partnership with Pfizer in 2022, CytoReason has onboarded three more major pharma collaborators and extended its modeling capabilities into new disease areas. The company also published 20 peer-reviewed studies in 2023 across high-impact journals.
Industry Leaders Speak
David Harel, Co-founder and CEO, CytoReason:
“This funding highlights the value of data modeling in pharma. With support from global tech and science leaders, we’re scaling our impact on drug development worldwide.”
Kimberly Powell, VP & GM, Healthcare, NVIDIA:
“By leveraging NVIDIA’s latest platforms, CytoReason has achieved over 10x acceleration in AI workloads—driving new predictive capabilities in life sciences.”
Dr. Mikael Dolsten, Chief Scientific Officer, Pfizer:
“Our collaboration with CytoReason enhances our immunology research and unlocks new drug development pathways.”
Bhooshi De Silva, Head of Strategic Capital, Thermo Fisher Scientific:
“This partnership merges powerful data assets with AI to reshape how R&D decisions are made.”
Jon Medved, CEO, OurCrowd:
“CytoReason is a standout example of how Israeli AI startups are transforming global healthcare.”
Structured financing was provided by Bank Hapoalim. CytoReason was advised by Nomura Securities and Locust Walk.
About CytoReason
CytoReason builds computational disease models that help pharma and biotech companies make data-driven R&D decisions. Its platform supports target prioritization, patient stratification, and pipeline optimization by integrating public and proprietary datasets into dynamic biological insights.
By